|
|
| | Pelidotin Basic information |
| Product Name: | Pelidotin | | Synonyms: | Pelidotin;MC-VC-PABC-Aur0101;L-Valinamide, N-[[[4-[[N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-2-methylalanyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[...;Pelidotin/ mcVC-PABC 0101 | | CAS: | 1438849-92-3 | | MF: | C68H100N12O14S | | MW: | 1341.68 | | EINECS: | | | Product Categories: | | | Mol File: | 1438849-92-3.mol |  |
| | Pelidotin Chemical Properties |
| Boiling point | 1380.8±65.0 °C(Predicted) | | density | 1.222±0.06 g/cm3(Predicted) | | pka | 10.56±0.46(Predicted) | | form | Solid | | color | White to off-white |
| | Pelidotin Usage And Synthesis |
| Uses | MC-VC-PABC-Aur0101 is a agent-linker conjugate for ADC with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC. | | IC 50 | Auristatin | | References | [1] Samantha Congreve, et al. Antibody drug conjugates (ADC) Current status and mapping of ADC:s in clinical programs. |
| | Pelidotin Preparation Products And Raw materials |
|
|
Tag:Pelidotin(1438849-92-3)
Related Product Information
|
|
Glycinamide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]-
L-Ornithinamide, N6-[39-[bis(1-deoxy-D-glucitol-1-yl)amino]-1-oxo-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxanonatriacont-1-yl]-N2-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-lysyl-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-1...
PSMA-617
Deruxtecan
Mal-VC-PAB-DM1
MC-VA-PAB-Exatecan
|